The Lombardi Comprehensive Cancer Center (LCCC) supports high priority, innovative, pilot or phase I institutional trials focusing on initial early phase testing of a candidate agent or device for the diagnosis, prevention, detection or treatment of cancer. Potential institutional trials arise from LCCC's Research Programs and are developed within disease-focused groups. Letters-of-intent (LOIs) are submitted to LCCC's Protocol Review and Monitoring System (PRMS) Committee for scientific review and prioritization. If the proposed trial is requesting internal funding and is approved by PRMS, the LOI and PRMS reviews are forwarded to the Resource Allocation Subcommittee for Investigator Initiated Trials (RACIIT). RACIIT identifies those trials that are eligible for and merit Early Phase Clinical Research Support (EPCRS) or institutional funding. Once a PRMS-approved LOI is assured of funding, a full protocol can be written and submitted back to PRMS for final approval. If approved by the PRMS and the Institutional Review Board (IRB), previously committed funds are released to provide support for research nursing and/or data management through the Integrated Clinical Research Management Office (ICRMO), and, if designated, for correlative studies. The translation of basic science to the clinic has resulted in the testing of a series of agents that have been developed at LCCC. The strong emphasis on translational research and drug development is reflected in the development and clinical testing of agents targeting growth factors, oncogenic mutations, activated pathways and, more recently, immune checkpoints. These early phase clinical trials are developed on a background of bench-to-bedside-back to bench translational research. Thus, clinical trials can be born out of institutional basic science research (e.g., CDK4/6 inhibition in Gl cancers);out of a combination of clinical research interconnected with basic science research (e.g., PPARy + RXR agonist;Nilotinib + Cetuximab);or clinically driven research that requires strong basic scientific correlates (e.g., rational combination of temsirolimus plus capecitabine;a pilot study of stereotactic radiosurgery with concurrent gemcitabine, a pilot study of tremelimumab in patients with hepatocellular cancer, and studies testing the feasibility of using conditionally reprogrammed cells to predict treatment outcome).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA051008-21
Application #
8698925
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-15
Project End
2019-04-30
Budget Start
2014-09-09
Budget End
2015-04-30
Support Year
21
Fiscal Year
2014
Total Cost
$54,575
Indirect Cost
$19,478
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Rao, Guanhua; Pierobon, Mariaelena; Kim, In-Kyu et al. (2017) Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Sci Rep 7:7066
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2017) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother :
Vietsch, Eveline E; Graham, Garrett T; McCutcheon, Justine N et al. (2017) Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genet 218-219:39-50
Lynce, Filipa; Barac, Ana; Tan, Ming T et al. (2017) SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. Oncologist 22:518-525
Walker, Logan C; Marquart, Louise; Pearson, John F et al. (2017) Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet 25:432-438
Zhang, Yong-Wei; Nasto, Rochelle E; Jablonski, Sandra A et al. (2017) RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells. Bio Protoc 7:
DeVito, Stephen; Woodrick, Jordan; Song, Linze et al. (2017) Mutagenic potential of hypoxanthine in live human cells. Mutat Res 803-805:9-16
Wang, Hongkun; Wang, Ying; Kota, Krishna K et al. (2017) Strong associations between chromosomal aberrations in blood lymphocytes and the risk of urothelial and squamous cell carcinoma of the bladder. Sci Rep 7:13493
Parodi, Daniela A; Greenfield, Morgan; Evans, Claire et al. (2017) Alteration of Mammary Gland Development and Gene Expression by In Utero Exposure to Cadmium. Int J Mol Sci 18:
Casero, David; Gill, Kirandeep; Sridharan, Vijayalakshmi et al. (2017) Space-type radiation induces multimodal responses in the mouse gut microbiome and metabolome. Microbiome 5:105

Showing the most recent 10 out of 997 publications